Transo Pharm Cannabidiol Header Transo Pharm Cannabidiol Header

X

Find Drugs in Development News & Deals for Cannabidiol

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

0

Australia

Australia

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

SERVICES

0

Details:

Under the terms of the agreement, Vectura will undertake formulation screening studies, manufacturing process optimisation studies and stability assessments, as well as manufacturing a laboratory-scale batch of IHL-216A (Cannabidiol) to support toxicological studies.


Lead Product(s): Cannabidiol,Isoflurane

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: IHL-216A

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Incannex Healthcare

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 22, 2021

Skyepharma Company Banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agitation disorder, etc.


Lead Product(s): Cannabidiol

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 01, 2023

Medipharm CB

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

MediPharmto design, manufacture and supply a liquid oral cannabis study drug for the Phase 2 Life’s end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) study, to be conducted in the U.S., across 20 sites, to treat hospice-eligible patients diagnosed with dementia and agitation.


Lead Product(s): Cannabidiol,Tetrahydrocannabinol

Therapeutic Area: Neurology Product Name: T2:C100

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: National Institutes of Health

Deal Size: $16.0 million Upfront Cash: Undisclosed

Deal Type: Funding August 09, 2022

Medipharm CB

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

New CBG products include Advanced Formula, which is a CBG:CBD 1:2 oil, and Northbound, which is a high CBG vape cartridge with CBD inspired by The White and Appalachia strains.


Lead Product(s): Cannabigerol,Cannabidiol

Therapeutic Area: Neurology Product Name: CBG:CBD

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 05, 2022

Medipharm CB

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

Naturally derived oil and inhalable cannabigerol (cannabinoid) products added to MediPharm's wellness portfolio – the benefits of CBG without the effects of THC.


Lead Product(s): Cannabidiol,Cannabigerol

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 05, 2022

Medipharm CB

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

McMaster University researchers using MediPharm Labs’ CBD50 formula and CBD:THC 10:2 formulation, which has the same as MediPharm Labs’ CBD25, have received a No Objection Letter from Health Canada to begin recruiting human subjects for a placebo-controlled trial.


Lead Product(s): Cannabidiol

Therapeutic Area: Sleep Product Name: CBD50

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: McMaster University

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 31, 2021

Medipharm CB

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

Three initial proposed clinical trials will evaluate the effectiveness of proprietary THC and CBD (cannabidiol) drug candidates for multiple indications including Pain, Insomnia associated with Major Depression, and Uremic Pruritus.


Lead Product(s): Cannabidiol,Tetrahydrocannabinol

Therapeutic Area: Sleep Product Name: Undisclosed

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: McMaster University

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 21, 2021

Medipharm CB

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

Patients in Germany are now able to access GMP-certified quality medical cannabis from STADA through local pharmacies under the brand – CannabiSTADA, distributed through STADAPHARM, a direct subsidiary of STADA.


Lead Product(s): Tetrahydrocannabinol,Cannabidiol

Therapeutic Area: Neurology Product Name: CannabiSTADA

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: European Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement April 01, 2021

Medipharm CB

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

As a result of agreement, patients in Germany are now able to access GMP-certified quality medical cannabis from STADA through local pharmacies under the brand – CannabiSTADA (cannabidiol), distributed through STADAPHARM, a direct subsidiary of STADA.


Lead Product(s): Cannabidiol,Tetrahydrocannabinol

Therapeutic Area: Gastroenterology Product Name: CannabiStada

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: STADA Arzneimittel

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement April 01, 2021

Medipharm CB

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

Cannabinoid oral solution has received approval for the treatment of several neurological disorders. It functions by stimulating two receptors, cannabinoid receptor type 1 and type 2, within the endocannabinoid system, maintaining body's homeostatis.


Lead Product(s): Cannabidiol

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 15, 2023

Biophore CB

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

SCI-210 a combination of cannabidiol (CBD) and CannAmide™ (SciSparc’s Palmitoylethanolamide), which is being evaluated for the treatment of Autism Spectrum Disorder in children between 5 and 18 years.


Lead Product(s): Cannabidiol,Palmitoylethanolamide

Therapeutic Area: Neurology Product Name: SCI-210

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 08, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

LPT CBD (cannabinoid) is a loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. It is being evaluated for the treatment of epilepsy and for pain management.


Lead Product(s): Cannabidiol

Therapeutic Area: Neurology Product Name: LPT-CBD

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 26, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The exclusive supply agreement is for the Company’s proprietary topical products that have been commercialized in the Canadian market under the RHO Phyto brand, including AVCN-583601, Ultra-CBD cream, a CBD localized cream developed to target dermatology conditions.


Lead Product(s): Cannabidiol

Therapeutic Area: Rare Diseases and Disorders Product Name: AVCN-583601

Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement February 05, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SCI-210 (cannabidiol) is a combination of cannabidiol (CBD) and CannAmide™ (SciSparc’s Palmitoylethanolamide), which is being evaluated in clinical trials for the treatment of autism spectrum disorder.


Lead Product(s): Cannabidiol,Cannamide

Therapeutic Area: Neurology Product Name: SCI-210

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 29, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, Sipp Industries will manufacture SinuSave® CBD Nasal Spray products. SinuSave® CBD is proven to be bacteriostatic and bactericidal.


Lead Product(s): Cannabidiol

Therapeutic Area: Neurology Product Name: SinuSave

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: SinuSave

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 23, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Clasepi (cannabidiol) is an oral CB1 receptor negative allosteric modulator. It has been launched in India for the treatment of patients with Epilepsy.


Lead Product(s): Cannabidiol

Therapeutic Area: Neurology Product Name: Clasepi

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 12, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SAP021 (cannabidiol) is an oral CB1 receptor negative allosteric modulator. It is being evaluated in phase 1 clinical trials for the treatment of neurological diseases.


Lead Product(s): Cannabidiol

Therapeutic Area: Neurology Product Name: SAP021

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 19, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.


Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol

Therapeutic Area: Neurology Product Name: RHO Phyto

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $0.8 million Upfront Cash: Undisclosed

Deal Type: Private Placement December 04, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Epidiolex (cannabidiol) is an oral CB receptor CB1 receptor negative allosteric modulator. It is now approved for the treatment of seizures associated with Lennox-Gastaut syndrome & Dravet syndrome in patients 2 years of age and older.


Lead Product(s): Cannabidiol

Therapeutic Area: Rare Diseases and Disorders Product Name: Epidiolex

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 23, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SAP021 (cannabidiol) is an oral CB1 receptor negative allosteric modulator. It is being evaluated in phase 1 clinical trials for the treatment of neurological diseases.


Lead Product(s): Cannabidiol

Therapeutic Area: Neurology Product Name: SAP021

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 21, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Cannabidiol is a CB1 receptor negative allosteric modulator (NAM), which is being evaluated in preclinical studies for the treatment of Pain.


Lead Product(s): Cannabidiol

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 23, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The Company intends to use the net proceeds to fund the Company's pre-investigational new drug meeting regarding the human application of the Company's products, including Cannabidiol.


Lead Product(s): Cannabidiol

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Research Capital Corporation

Deal Size: $1.6 million Upfront Cash: Undisclosed

Deal Type: Private Placement October 20, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The Company intends to use the net proceeds from the Offering to fund the Company's pre-investigational new drug meeting with the United States FDA regarding the human application and expansion of the Company's derma-cosmetic product distribution.


Lead Product(s): Cannabidiol,Menthol,Camphor

Therapeutic Area: Neurology Product Name: Relief & Go

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Research Capital Corporation

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Private Placement October 12, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Through the acquisition, Harmony gets the opportunity to advance the development of a treatment for the symptoms of Fragile X syndrome and other rare neuropsychiatric disorders including, Zygel, the first and only pharmaceutically manufactured, synthetic cannabidiol.


Lead Product(s): Cannabidiol

Therapeutic Area: Genetic Disease Product Name: Zygel

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Harmony Biosciences

Deal Size: $200.0 million Upfront Cash: $200.0 million

Deal Type: Acquisition October 11, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SCI-210 is a proprietary combination of cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA, clinical trial will investigate SCI-210 in comparison to CBD monotherapy in treating ASD.


Lead Product(s): Cannabidiol,Cannamide

Therapeutic Area: Neurology Product Name: SCI-210

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 29, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Endosane is focused on preclinical studies to evaluate the brain delivery characteristics of sol-gel technology and whether pharmacologically relevant concentrations of Cannabidiol can be achieved with this technology.


Lead Product(s): Cannabidiol

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Endosane Pharmaceuticals

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 18, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

Cannabidiol, a chemical compound from the cannabis plant, that help improvement in social and motor problems, a reduction in epilepsy and an increase in life expectancy in Leigh syndrome mouse models.


Lead Product(s): Cannabidiol

Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 14, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Cannabidiol is a topical CB1 receptor negative allosteric modulator (NAM), which is being evaluated in phase 1 clinical studies for the treatment of Diabetic Foot.


Lead Product(s): Cannabidiol

Therapeutic Area: Podiatry Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 15, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Through the acquisition, Harmony gets the opportunity to advance the development of a treatment for the symptoms of Fragile X syndrome and other rare neuropsychiatric disorders including, Zygel, the first and only pharmaceutically manufactured, synthetic cannabidiol.


Lead Product(s): Cannabidiol

Therapeutic Area: Genetic Disease Product Name: Zygel

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Harmony Biosciences

Deal Size: $200.0 million Upfront Cash: $200.0 million

Deal Type: Acquisition August 14, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The agreement aims to perform a clinical pharmacology study of the uptake of cannabidiol (CBD) in a formulation which can be delivered as a pill orally.


Lead Product(s): Cannabidiol

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Hebrew University

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement August 07, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The company expects to use the net proceeds to advance its clinical development programs, including MIRA1a (synthetic tetrahydrocannabinol analog), being developed as the first prescription drug to target the CB1 and CB2 receptors for chronic pain and anxiety.


Lead Product(s): Tetrahydrocannabinol Analog,Cannabidiol

Therapeutic Area: Psychiatry/Psychology Product Name: MIRA1A

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: Kingswood Investments

Deal Size: $8.9 million Upfront Cash: Undisclosed

Deal Type: Public Offering August 07, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.


Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol

Therapeutic Area: Neurology Product Name: RHO Phyto

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $1.4 million Upfront Cash: Undisclosed

Deal Type: Private Placement August 02, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The proceeds will be used for production, raw material and laboratory costs associated with production of GMP cannabinoid medicines CannEpil, a high-CBD, low-THC formulation delivered by an oral mucosal solution and CogniCann, an oral spray that combines THC and CBD.


Lead Product(s): Cannabidiol,Tetrahydrocannabinol

Therapeutic Area: Neurology Product Name: CannEpil

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Oberon Capital

Deal Size: $2.6 million Upfront Cash: Undisclosed

Deal Type: Financing August 01, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including rheumatoid arthritis.


Lead Product(s): Cannabidiol,Hydroxychloroquine Sulphate

Therapeutic Area: Immunology Product Name: IHL-675A

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 26, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SCI-210 is a proprietary combination of cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA, clinical trial will investigate SCI-210 in comparison to CBD monotherapy in treating ASD.


Lead Product(s): Cannabidiol,Cannamide

Therapeutic Area: Neurology Product Name: SCI-210

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: Negev Autism Center Soroka University Medical Center

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 14, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including rheumatoid arthritis.


Lead Product(s): Cannabidiol,Hydroxychloroquine Sulphate

Therapeutic Area: Immunology Product Name: IHL-675A

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 13, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The agreement aims for the supply and distribution of PBIO's UltraShear™-processed nanoemulsified cannabidiol in a hemp-derived, best-in-class, super-fast acting, highly bioavailable, all natural, preservative-free, and highly potent Nano-CBD Topical Spray.


Lead Product(s): Cannabidiol

Therapeutic Area: Dermatology Product Name: UltraShear Nano-CBD

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Crème de Canna

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 10, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The agreement aims for the development and distribution of UltraShear Technology enhanced health and wellness products including, Nano-CBD (cannabidiol), a highly bioavailable, best-in-class topical spray.


Lead Product(s): Cannabidiol

Therapeutic Area: Neurology Product Name: Nano-CBD

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Somalab

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 05, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Through the acquisition, Lucy adds Wesana’s psilocybin and cannabidiol (CBD) combination investigational therapy, SANA-013 to its existing business of psychedelics manufacturing. SANA-013 is being developed for the treatment of several mental health/CNS-related conditions.


Lead Product(s): Psilocybine,Cannabidiol

Therapeutic Area: Psychiatry/Psychology Product Name: SANA-013

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Lucy Scientific Discovery

Deal Size: $0.5 million Upfront Cash: $0.4 million

Deal Type: Acquisition July 05, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, Avicanna and Medipharm intend to commercialize various formulations of Avicanna’s proprietary cannabinoid-based Self-Emulsifying Drug Delivery Systems (SEDDS) technology capsules for the Canadian and international markets.


Lead Product(s): Cannabidiol

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: MediPharm Labs

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 26, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The collaboration aims to focus on Avicanna’s proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.


Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol

Therapeutic Area: Neurology Product Name: RHO Phyto

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Applied Research Centre at Langara College

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 13, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

IHL-675A is a fixed dose combination of cannabidiol and hydroxychloroquine. It is being investigated for rheumatoid arthritis, inflammatory bowel disease and lung inflammation.


Lead Product(s): Cannabidiol,Hydroxychloroquine Sulphate

Therapeutic Area: Immunology Product Name: IHL-675A

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 03, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Cannabinoids is a selective serotonin reuptake inhibitor (SSRI) which is being developed for treating antidepressant-induced female sexual dysfunction.


Lead Product(s): Cannabidiol

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 29, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Nantheia ATL5 creates new potential for cannabidiol therapeutics, having the ability to reduce opioid intake for individuals being treated for OUD and facilitating voluntary opioid sparing.


Lead Product(s): Cannabidiol

Therapeutic Area: Psychiatry/Psychology Product Name: Nantheia ATL5

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 28, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Starseed continues to solidify its position as an industry leader leveraging its innovative medical cannabis products to include unique CBD chewing gum. Cannabis-infused gum is made using CBD isolate in partnership with NordicCan.


Lead Product(s): Cannabidiol

Therapeutic Area: Neurology Product Name: Starseed

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: NordicCan

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 27, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

CVSI-007 contains nicotine and cannabidiol which supports the cessation of smokeless tobacco use and addiction, if approved it'll be the first and only treatment for smokeless tobacco addiction.


Lead Product(s): Nicotine,Cannabidiol

Therapeutic Area: Psychiatry/Psychology Product Name: CVSI-007

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 23, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Through the acquisition, Lucy will add Wesana’s psilocybin and cannabidiol (CBD) combination investigational therapy, SANA-013 to its existing business of psychedelics manufacturing. SANA-013 is being developed for the treatment of several mental health/CNS-related conditions.


Lead Product(s): Psilocybine,Cannabidiol

Therapeutic Area: Psychiatry/Psychology Product Name: SANA-013

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Lucy Scientific Discovery

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition March 21, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

Nantheia ATL5 creates new potential for cannabidiol therapeutics, having the ability to reduce opioid intake for individuals being treated for OUD and facilitating voluntary opioid sparing.


Lead Product(s): Cannabidiol

Therapeutic Area: Psychiatry/Psychology Product Name: Nantheia ATL5

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Ananda Scientific

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 14, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Cannabidiol, a plant-derived cannabis-based medicine which is act CB receptor agonist, is administered orally for the treatment of traumatic brain injuries in preclinical studies.


Lead Product(s): Cannabidiol

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 06, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Epidyolex (cannabidiol), plant-derived cannabis-based medicine which is act CB receptor agonist, administered as an oral solution, is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year of age and older.


Lead Product(s): Cannabidiol

Therapeutic Area: Rare Diseases and Disorders Product Name: Epidyolex

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 31, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY